MC-S

medicine to improve the body's immune system and assist in prevention of foreign cell growth, cold viruses, flu and secondary infections.

Research

Research of MC-S has been completed in Australia primarily at the University of Newcastle. The in-vivo and in-vitro immune-stimulating properties of MC-S indicate that it is a biological response modifier^(1,2,4). Research has shown that MC-S promotes the proliferation of Natural killer cells, T helper cells, cytotoxic T cells and B cells (peripheral blood lymphocytes) [The University of Newcastle Research Associates (TUNRA), The School of Environmental and Life Sciences, University of Newcastle, 2007, [http://mc-s.com.au/researchpapers/An%20in%20vitro%20proliferation%20study%20using%20the%20commercial%20nutraceutical%20mix%20on%20non-stimulated%20human%20lymphocytes.pdf An in vitro proliferation study using the commercial nutraceutical MC-S on non-stimulated human lymphocytes] ] .This is likely due to the up regulation of cytokine production [The South Asian Epidemiology Research Group 2008, [http://mc-s.com.au/researchpapers/The%20in%20vivo%20in%20vitro%20anti-HIV%20activity%20and%20cellular%20immune%20stimulating%20effects%20of%20the%20pharmacological%20compound,%20MC-S.pdf The in vivo in vitro anti-HIV activity and cellular immune stimulating effects of the pharmacological compound, MC-S] ] .The anti-tumour activity of MC-S has been shown in-vitro to significantly inhibit the growth of breast cancer, prostate cancer, colon cancer and melanoma cells in hypothesized cell culture conditions (μg/ml) comparable to human therapeutic doses.⁽⁴⁾ A double blind placebo controlled study monitoring healthy adults showed that MC-S was effective as an anti-viral agent which can significantly reduce the incidents of colds, flu and secondary infections in-vivo [Human Health Research Australia, Clark D, 2007. [http://mc-s.com.au/researchpapers/A%20double%20blind%20placebo%20controlled%20study%20monitoring%20healthy%20adults%20consuming%20a%20commercial%20preparation%20of%20nutraceuticals.pdf A double blind placebo controlled study monitoring healthy adults taking the commercial preparation of MC-S] ] .

Benefits and effects

The commercial nutraceutical MC-S has been shown to inhibit cancer cell growth, HIV induced syncytia formation, significantly increased the expression of the T-cell growth factor Interleukin 2 (IL-2) and the anti-viral cytokine interferon (IFN) in-vivo^(2,4). This research has demonstrated that the commercial nutraceutical MC-S is selective in its action by inhibiting cancer cell proliferation while enhancing immune cell production at comparable doses [The University of Newcastle Research Associates (TUNRA), The School of Environmental and Life Sciences, University of Newcastle, 2008, [http://mc-s.com.au/researchpapers/The%20commercial%20nutraceutical%20Metabolic%20Cell-Support%20inhibits%20cancer%20cell%20growth.pdf The commercial nutraceutical MC-S inhibits cancer cell growth] ] . These findings indicate MC-S may offer additional adjunctive benefits to standard oncology / immunology protocols^(1,2,3,4).

Official recognition

World Health Organisation (WHO) - WHOCPP 08/0533

World Anti-Doping Agency (WADA) certificate of analysis: 45351. Approval was given to MC-S in 2008 so that it can be legally used by athletes [ [http://www.mc-s.com.au/researchpapers/HFL.pdf HFL England, WADA approved laboratory, UKAS Testing Laboratory No: 1187, MC-S (Metabolic Cell-Support) Certificate of analysis: 45351, 2008] ] .

Therapeutic Goods Administration (TGA) AUST L138610

Ingredients

The compounds of MC-S have been extensively researched and been shown to be safe for human consumption and beneficial to the immune system [Kidd P. M. 2000. [http://www.ncbi.nlm.nih.gov/pubmed/10696116 The use of mushroom glucans and proteoglycans in cancer treatment. Alternative Medicine Review, 5, 4-27] ] .
*Ganoderma lucidum
*Lentinan
*Polysaccharide Peptide (PSP)
*Polysaccharide-K (PSK)
*Astragalus membranaceus
*Ascorbic acid

References